- 米国企業
- PRESSURE BIOSCIENCES INC
PRESSURE BIOSCIENCES INCPBIO
時価総額
$276.6万
PER
| 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Net loss | -3,450,205 | -4,084,427 | -4,612,540 | -7,415,298 | -2,706,984 | -10,715,561 | -9,699,318 | -11,660,917 | -16,005,543 | -20,153,486 | -16,076,678 |
| Gain on loan forgiveness | - | - | - | - | - | - | - | - | - | 734,077 | 10,000 |
| Non-cash lease expense | - | - | - | - | - | - | - | - | - | 65,194 | 113,470 |
| Common stock and warrants issued for interest | - | - | - | - | - | - | - | - | - | - | 3 |
| Depreciation and amortization | 107,519 | 79,563 | 65,714 | 25,288 | 17,939 | 8,576 | 94,271 | 123,596 | 127,301 | 110,128 | 119,788 |
| Accretion of interest and amortization of debt discount | - | - | - | - | - | - | -1,517,394 | -1,353,483 | -5,436,863 | -6,738,802 | -1,777,863 |
| Common stock and warrants issued for debt extension | - | - | - | - | -5,044 | 185,452 | - | -795,089 | -3,575,878 | -130,279 | -2,331,398 |
| Allowance for inventory reserve | - | - | - | - | - | - | - | - | - | - | 641,815 |
| Stock-based compensation expense | 133,193 | 136,796 | 101,125 | 208,989 | 379,964 | 406,427 | 592,477 | 1 | 488,792 | 254,615 | 215,098 |
| (Gain) loss on investment in equity securities | - | - | - | - | - | - | - | - | - | - | 3,662 |
| Common stock and warrants issued for services | - | - | - | - | - | 31,000 | 1 | - | 179,077 | 794,562 | 446,670 |
| Accounts receivable | -84,988 | -68,630 | 124,387 | -158,766 | 196,233 | -74,472 | 267,982 | -245,428 | -98,174 | 23,518 | 140,628 |
| Inventories | -95,651 | -186,686 | 113,876 | 187,820 | -133,087 | 111,978 | 56,107 | -78,814 | -24,949 | 554,787 | 180,644 |
| Prepaid expenses and other assets | -20,099 | -4,333 | 18,631 | 15,722 | 44,201 | -59,312 | -289,544 | 42,815 | 101,387 | 107,681 | -165,090 |
| Accounts payable | - | - | - | -94,392 | -534,140 | 182,014 | 69,593 | 156,908 | -43,819 | -226,771 | 109,314 |
| Accrued employee compensation | -61,099 | 29,995 | 8,014 | 18,662 | 73,587 | 119,104 | 88,232 | -5,732 | -33,622 | 15,106 | 49,567 |
| Operating lease liability | - | - | - | - | - | - | - | - | - | -65,194 | -113,470 |
| Deferred revenue and other accrued expenses | - | - | - | - | - | - | 442,179 | 1 | 4 | 1 | 3 |
| Net cash used in operating activities | -2,164,801 | -2,342,603 | -3,210,578 | -3,819,746 | -3,805,851 | -3,904,549 | -5,695,904 | -6,327,578 | -4,883,194 | -4,868,573 | -4,478,041 |
| Purchases of property plant and equipment | - | 58,749 | 7,139 | 9,412 | 7,203 | 21,825 | - | 23,375 | 1,663 | 122,945 | 20,755 |
| Net cash used in investing activities | - | -58,749 | -7,139 | -9,412 | -7,203 | -171,825 | - | -23,375 | -796,663 | -122,945 | -20,755 |
| Net proceeds from the issuance of Series AA Convertible Preferred Stock | - | - | - | - | - | - | 3 | 3 | 150,000 | 1 | - |
| Sale of common stock | 377,453 | - | 149,165 | - | 530,965 | - | - | - | - | - | 25,000 |
| Proceeds from stock option exercises | - | - | - | - | - | - | - | - | - | 14,773 | 17,443 |
| Net proceeds from convertible debt | 1 | 1 | 1 | 6 | 2 | 2 | 6 | 7 | 8 | 6 | 5 |
| Net proceeds from non-convertible debt - third party | - | - | - | 1 | 1 | 3 | 2 | 3 | 1 | - | 3 |
| Net proceeds from non-convertible debt - related party | 98,675 | 222,000 | 302,252 | 6,300 | 116,667 | - | 168,600 | 259,500 | 283,700 | 254,600 | 866,350 |
| Payments on convertible debt | 101,556 | -350,000 | 303,100 | 3 | 107,000 | 925,541 | 4 | 4 | 3 | 2 | 2 |
| Payments on non-convertible debt - related party | - | -180,304 | 416,691 | 12,300 | 20,000 | - | 103,600 | 193,000 | 199,200 | 354,600 | 315,300 |
| Payments on non-convertible debt | - | - | - | 587,949 | 947,702 | 2 | 2 | 2 | 1 | 2 | 2 |
| Net cash provided by financing activities | 2 | 2 | 4 | 3 | 4 | 4 | 6 | 6 | 6 | 5 | 4 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | - | - | - | - | - | - | - | -73,493 | -11,085 | 113,771 | -128,446 |
| Interest paid in cash | - | - | - | - | - | 533,532 | 1 | 3 | 764,600 | 921,569 | 1 |
| Early ASU 2020-06 adoption | - | - | - | - | - | - | - | - | - | - | 473,027 |
| Common stock issued with debt | - | - | - | - | - | - | - | - | - | - | 873,854 |
| Discount from warrants issued with debt | - | - | - | - | - | - | - | - | - | 1 | 93,576 |
| Common stock issued in lieu of cash for dividend | - | - | - | - | - | - | - | - | - | 184,274 | 386,300 |
| Preferred stock dividends | - | - | - | - | - | - | - | - | - | 2 | 2 |
| Conversion of preferred stock for common stock | - | - | - | - | - | - | - | - | - | - | 44 |
| Conversion of debt and interest into common stock | - | - | - | - | - | - | - | - | - | 3 | 467,092 |
| Discount due to beneficial conversion feature | - | - | - | - | - | - | - | - | - | 1 | - |
| Recognition of right of use asset and liability | - | - | - | - | - | - | - | - | - | 239,327 | - |